Gabriella Cohn Cedermark

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BJU INTERNATIONAL. 2024;133(6):717-724

Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours

Gerdtsson A; Negaard HFS; Almas B; Bergdahl AG; Cohn-Cedermark G; Glimelius I; Halvorsen D; Haugnes HS; Hedlund A; Hellstrom M; Holmberg G; Karlsdottir A; Kjellman A; Larsen SM; Thor A; Wahlqvist R; Stahl O; Tandstad T
Article: BJU INTERNATIONAL. 2023;132(3):329-336

Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients

Gerdtsson A; Torisson G; Thor A; Bergdahl AG; Almas B; Hakansson U; Tornblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Article: BRITISH JOURNAL OF CANCER. 2023;128(12):2261-2269

Risk and mortality of testicular cancer in patients with neurodevelopmental or other psychiatric disorders

Jansson AK; Soderling J; Reutfors J; Thor A; Skold C; Cohn-Cedermark G; Stahl O; Smedby KEE; Pettersson A; Glimelius I
Article: EUROPEAN UROLOGY ONCOLOGY. 2022;5(2):235-243

Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group

Gerdtsson A; Thor A; Bergdahl AG; Almas B; Hakansson U; Tornblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Article: EUROPEAN UROLOGY ONCOLOGY. 2020;3(3):382-389

Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group

Gerdtsson A; Hakansson U; Tornblom M; Jancke G; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(12):1322-1331

Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma

Fischer S; Tandstad T; Cohn-Cedermark G; Thibault C; Vincenzi B; Klingbiel D; Albany C; Necchi A; Terbuch A; Lorch A; Aparicio J; Heidenreich A; Hentrich M; Wheater M; Langberg CW; Stahl O; Fankhauser CD; Hamid AA; Koutsoukos K; Shamash J; White J; Bokemeyer C; Beyer J; Gillessen S
Article: PEDIATRIC SURGERY INTERNATIONAL. 2020;36(4):471-475

The overall risk of malignancies is not increased in patients with Hirschsprung disease

Granstrom AL; Cohn-Cedermark G; Wester T
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2019;37(11):809.e19-809.e25

The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3)

Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Stahl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Article: PLOS MEDICINE. 2019;16(6):e1002816

Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study

Al-Jebari Y; Glimelius I; Nord CB; Cohn-Cedermark G; Stahl O; Tandstad T; Jensen A; Haugnes HS; Daugaard G; Rylander L; Giwercman A
Article: ANNALS OF ONCOLOGY. 2019;30(4):604-611

Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment

Weibring K; Nord C; Stahl O; Eberhard J; Sandberg K; Johansson H; Arver S; Giwercman A; Cohn-Cedermark G
Article: ACTA ONCOLOGICA. 2018;57(10):1401-1406

Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

Langberg MK; Berglund-Nord C; Cohn-Cedermark G; Haugnes HS; Tandstad T; Langberg CW
Article: ANNALS OF ONCOLOGY. 2018;29(8):1658-1686

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

Honecker F; Aparicio J; Berney D; Beyer J; Bokemeyer C; Cathomas R; Clarke N; Cohn-Cedermark G; Daugaard G; Dieckmann K-P; Fizazi K; Fossa S; Germa-Lluch JR; Giannatempo P; Gietema JA; Gillessen S; Haugnes HS; Heidenreich A; Hemminki K; Huddart R; Jewett MAS; Joly F; Lauritsen J; Lorch A; Necchi A; Nicolai N; Oing C; Oldenburg J; Ondrus D; Papachristofilou A; Powles T; Sohaib A; Stahl O; Tandstad T; Toner G; Horwich A
Article: EUROPEAN JOURNAL OF CANCER. 2018;94:16-25

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.

Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Bokemeyer C
Article: ASIAN JOURNAL OF ANDROLOGY. 2017;19(5):538-542

Androgen receptor gene CAG and GGN repeat lengths as predictors of recovery of spermatogenesis following testicular germ cell cancer treatment

Bogefors K; Giwercman YL; Eberhard J; Stahl O; Cavallin-Stahl E; Cohn-Cedermark G; Arver S; Giwercman A
Article: ANNALS OF ONCOLOGY. 2016;27(7):1299-1304

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)

Tandstad T; Stahl O; Dahl O; Haugnes HS; Hakansson U; Karlsdottir A; Kjellman A; Langberg CW; Laurell A; Oldenburg J; Solberg A; Soderstrom K; Stierner U; Cavallin-Stahl E; Wahlqvist R; Wall N; Cohn-Cedermark G
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(4):345-351

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

Feldman DR; Lorch A; Kramar A; Albany C; Einhorn LH; Giannatempo P; Necchi A; Flechon A; Boyle H; Chung P; Huddart RA; Bokemeyer C; Tryakin A; Sava T; Winquist EW; De Giorgi U; Aparicio J; Sweeney CJ; Cohn Cedermark G; Beyer J; Powles T
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2016;50(1):9-13

The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway

Tandstad T; Stahl O; Hakansson U; Wahlqvist R; Klepp O; Cavallin-Stahl E; Cohn-Cedermark G
Article: EUROPEAN UROLOGY. 2015;68(6):1054-1068

Guidelines on Testicular Cancer: 2015 Update

Albers P; Albrecht W; Algaba F; Bokemeyer C; Cohn-Cedermark G; Fizazi K; Horwich A; Laguna MP; Nicolai N; Oldenburg J
Article: ACTA ONCOLOGICA. 2015;54(10):1770-1780

Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment

Nord C; Olofsson S-E; Glimelius I; Cedermark GC; Ekberg S; Cavallin-Stahl E; Neovius M; Jerkeman M; Smedby KE
Article: ACTA ONCOLOGICA. 2015;54(4):493-499

Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols

Tandstad T; Solberg A; Hakansson U; Stahl O; Haugnes HS; Oldenburg J; Dahl O; Kjellman A; Angelsen A; Cohn-Cedermark G
Article: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(1):51-57

Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance

Kollmannsberger C; Tandstad T; Bedard PL; Cohn-Cedermark G; Chung PW; Jewett MA; Powles T; Warde PR; Daneshmand S; Protheroe A; Tyldesley S; Black PC; Chi K; So AI; Moore MJ; Nichols CR
Article: ANNALS OF ONCOLOGY. 2014;25(11):2167-2172

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Tandstad T; Stahl O; Hakansson U; Dahl O; Haugnes HS; Klepp OH; Langberg CW; Laurell A; Oldenburg J; Solberg A; Soderstrom K; Cavallin-Stahl E; Stierner U; Wahlquist R; Wall N; Cohn-Cedermark G
Article: ANDROLOGY. 2014;2(2):252-258

Inhibin B concentration is predictive for long-term azoospermia in men treated for testicular cancer

Isaksson S; Eberhard J; Stahl O; Cavallin-Stahl E; Cohn-Cedermark G; Arver S; Giwercman YL; Giwercman A
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2014;17(1):81-90

An expression signature at diagnosis to estimate prostate cancer patients' overall survival

Peng Z; Skoog L; Hellborg H; Jonstam G; Wingmo I-L; Hjalm-Eriksson M; Harmenberg U; Cedermark GC; Andersson K; Ahrlund-Richter L; Pramana S; Pawitan Y; Nister M; Nilsson S; Li C
Article: FRONTIERS IN ENDOCRINOLOGY. 2013;4:4

Association between polymorphisms in the aryl hydrocarbon receptor repressor gene and disseminated testicular germ cell cancer.

Brokken LJS; Lundberg-Giwercman Y; Rajpert-De Meyts E; Eberhard J; Ståhl O; Cohn-Cedermark G; Daugaard G; Arver S; Giwercman A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2013;42(1):109-117

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: Single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy

Cortes-Gonzalez JR; Castellanos E; Sandberg K; Eriksson M-H; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernas B; Brandberg Y; Marquez M; Kalkner K-M; Nilsson S
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2012;351(2):279-285

Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer

Brokken LJS; Lundberg-Giwercman Y; De-Meyts ER; Eberhard J; Stahl O; Cohn-Cedermark G; Daugaard G; Arver S; Giwercman A
Article: ACTAS UROLOGICAS ESPANOLAS. 2012;36(3):127-145

EAU Guidelines on Testicular Cancer: 2011 Update

Albers P; Albrecht W; Algaba F; Bokemeyer C; Cohn-Cedermark G; Fizazi K; Horwich A; Laguna MP
Article: ACTA ONCOLOGICA. 2012;51(2):168-176

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)

Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Stahl E; Cohn-Cedermark G
Article: ANNALS OF ONCOLOGY. 2012;23(1):59-64

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

Bachner M; Loriot Y; Gross-Goupil M; Zucali PA; Horwich A; Germa-Lluch J-R; Kollmannsberger C; Stoiber F; Flechon A; Oechsle K; Gillessen S; Oldenburg J; Cohn-Cedermark G; Daugaard G; Morelli F; Sella A; Harland S; Kerst M; Gampe J; Dittrich C; Fizazi K; De Santis M
Article: JOURNAL OF MEDICAL GENETICS. 2012;49(1):58-65

A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation

Dalgaard MD; Weinhold N; Edsgard D; Silver JD; Pers TH; Nielsen JE; Jorgensen N; Juul A; Gerds TA; Giwercman A; Giwercman YL; Cohn-Cedermark G; Virtanen HE; Toppari J; Daugaard G; Jensen TS; Brunak S; Rajpert-De Meyts E; Skakkebk NE; Leffers H; Gupta R
Article: UROLOGY. 2011;78(4):S427-S434

Diagnosis, Staging, and Risk Factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009

Albers P; Algaba F; Cohn-Cedermark G; DeSantis M; Kliesch S; Moul JW
Article: EUROPEAN UROLOGY. 2011;60(2):304-319

EAU Guidelines on Testicular Cancer: 2011 Update

Albers P; Albrecht W; Algaba F; Bokemeyer C; Cohn-Cedermark G; Fizazi K; Horwich A; Laguna MP
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):2032-2039

Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group

Olofsson S-E; Tandstad T; Jerkeman M; Dahl O; Stahl O; Klepp O; Bremnes RM; Cohn-Cedermark G; Langberg CW; Laurell A; Solberg A; Stierner U; Wahlqvist R; Wijkstrom H; Anderson H; Cavallin-Stahl E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(6):719-725

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

Tandstad T; Smaaland R; Solberg A; Bremnes RM; Langberg CW; Laurell A; Stierner UK; Stahl O; Cavallin-Stahl EK; Klepp OH; Dahl O; Cohn-Cedermark G
Article: EUROPEAN JOURNAL OF CANCER. 2011;47(3):413-419

Polymorphic variation in the androgen receptor gene: Association with risk of testicular germ cell cancer and metastatic disease

Vastermark A; Giwercman YL; Hagstromer O; De-Meyts ER; Eberhard J; Stahl O; Cedermark GC; Rastkhani H; Daugaard G; Arver S; Giwercman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(33):4906-4911

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

International Prognostic Factors Study Group; Lorch A; Beyer J; Bascoul-Mollevi C; Kramar A; Einhorn LH; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin KA; Lotz J-P; Germa Lluch JR; Powles T; Kollmannsberger CK
Article: ANNALS OF ONCOLOGY. 2010;21(9):1858-1863

Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study

Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Article: ANNALS OF ONCOLOGY. 2010;21 Suppl 5:v147-v154

Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Schmoll H-J; Jordan K; Huddart R; Pes MPL; Horwich A; Fizazi K; Kataja V; ESMO Guidelines Working Group
Article: ANNALS OF ONCOLOGY. 2010;21 Suppl 5:v140-v146

Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Schmoll H-J; Jordan K; Huddart R; Pes MPL; Horwich A; Fizazi K; Kataja V; ESMO Guidelines Working Group
Article: JOURNAL OF AFFECTIVE DISORDERS. 2010;122(3):260-266

Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality

Eberhard J; Stahl O; Cohn-Cedermark G; Cavallin-Stahl E; Giwercman Y; Rastkhani H; Rylander L; Eberhard-Gran M; Kvist U; Giwercman A
Article: JOURNAL OF SEXUAL MEDICINE. 2009;6(7):1979-1989

Sexual Function in Men Treated for Testicular Cancer

Eberhard J; Stahl O; Cohn-Cedermark G; Cavallin-Stahl E; Giwercman Y; Rylander L; Eberhard-Gran M; Kvist U; Fugl-Meyer KS; Giwercman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(13):2122-2128

Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program

Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrom H; Klepp O
Article: ACTA ONCOLOGICA. 2007;46(7):909-917

Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost:: A 6-year follow-up

Kalkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellstrom M; Nilsson S
Article: EUROPEAN UROLOGY. 2005;48(6):885-894

Guidelines on testicular cancer

Albers P; Albrecht W; Algaba F; Bokemeyer C; Cohn-Cedermark G; Horwich A; Klepp O; Laguna MP; Pizzocaro G
Article: CANCER. 2000;89(7):1495-1501

Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm

Cohn-Cedermark G; Rutqvist LE; Andersson R; Breivald M; Ingvar C; Johansson H; Jönsson PE; Krysander L; Lindholm C; Ringborg U
Article: CANCER. 2000;89(2):348-355

Trends in mortality from malignant melanoma in Sweden, 1970-1996

Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Johansson H; Ringborg U
Article: ACTA ONCOLOGICA. 1999;38(5):549-557

Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma

Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U
Article: ACTA ONCOLOGICA. 1998;37(5):463-470

Central nervous system metastases of cutaneous malignant melanoma -: A population-based study

Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Johansson H; Ringborg U
Visa fler

Alla övriga publikationer

Editorial comment: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(31):3525-3528

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

Tandstad T; Kollmannsberger CK; Roth BJ; Jeldres C; Gillessen S; Fizazi K; Daneshmand S; Lowrance WT; Hanna NH; Albany C; Foster R; Cedermark GC; Feldman DR; Powles T; Lewis MA; Grimison PS; Bank D; Porter C; Albers P; De Santis M; Srinivas S; Bosl GJ; Nichols CR
Letter: ANNALS OF ONCOLOGY. 2016;27(9):1809

Reply to 'The challenge to one course carboplatin in seminoma clinical stage 1' by Dieckmann and Anheuser

Tandstad T; Cohn-Cedermark G
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(20):2318-2319

Primum Non Nocere: What Hurts in Clinical Stage I Testicular Cancer?

Tandstad T; Cohn-Cedermark G
Review: ANNALS OF ONCOLOGY. 2015;26(5):833-838

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer

Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fossa SD; Germa-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondrus D; Rosti G; Stephenson AJ; Tandstad T
Review: ANDROLOGY. 2015;3(1):102-110

Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience

Cohn-Cedermark G; Stahl O; Tandstad T
Editorial comment: JOURNAL OF UROLOGY. 2013;189(6):2107-2108

Re: Early Salvage Radiation Therapy Combined with Short-Term Hormonal Therapy in Recurrent Prostate Cancer After Radical Prostatectomy: Single-Institution 4-Year Data on Outcome, Toxicity, Health-Related Quality of Life and Co-Morbidities from 184 Consecutive Patients Treated with 70 Gy

Cortes-Gonzalez JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lenneras B; Brandberg Y; Marquez M; Kalkner KM; Nilsson S
Review: ANNALS OF ONCOLOGY. 2013;24(4):878-888

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

Beyer J; Albers P; Altena R; Aparicio J; Bokemeyer C; Busch J; Cathomas R; Cavallin-Stahl E; Clarke NW; Classen J; Cohn-Cedermark G; Dahl AA; Daugaard G; De Giorgi U; De Santis M; De Wit M; De Wit R; Dieckmann KP; Fenner M; Fizazi K; Flechon A; Fossa SD; Germa Lluch JR; Gietema JA; Gillessen S; Giwercman A; Hartmann JT; Heidenreich A; Hentrich M; Honecker F; Horwich A; Huddart RA; Kliesch S; Kollmannsberger C; Krege S; Laguna MP; Looijenga LHJ; Lorch A; Lotz JP; Mayer F; Necchi A; Nicolai N; Nuver J; Oechsle K; Oldenburg J; Oosterhuis JW; Powles T; Rajpert-De Meyts E; Rick O; Rosti G; Salvioni R; Schrader M; Schweyer S; Sedlmayer F; Sohaib A; Souchon R; Tandstad T; Winter C; Wittekind C
Editorial comment: ACTA ONCOLOGICA. 2011;50:90-91

Introduction: Therapy with curative intent

Nilsson S; Cohn-Cedermark G; Wiklund P
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2010;78(3):S363

Clinical Results In 1004 Patients with Localized Prostate Cancer Treated with External Beam Radiotherapy, High Dose-rate 192-iridium Brachytherapy Boost, and Neo-adjuvant Hormonal Therapy

Castellanos E; Cohn-Cedermark G; Hjelm-Eriksson M; Nilsson J; Lundell M; Lundell G; Levitt S; Kalkner K; Nilsson S
Corrigendum: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(19):3263

Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program (vol 27, pg 2122, 2009)

Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrom H; Klepp O
Review: EUROPEAN UROLOGY. 2008;53(3):478-496

European consensus conference on diagnosis and treatment of germ cell cancer:: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG):: Part I

Krege S; Beyer J; Souchon R; Albers P; Albrecht W; Algaba F; Bamberg M; Bodrogi I; Bokemeyer C; Cavallin-Stahl E; Classen J; Clemm C; Cohn-Cedermark G; Culine S; Daugaard G; De Mulder PHM; De Santis M; de Wit M; de Wit R; Derigs HG; Dieckmann K-P; Dieing A; Droz J-P; Fenner M; Fizazi K; Flechon A; Fossa SD; del Muro XG; Gauler T; Geczi L; Gerl A; Germa-Lluch JR; Gillessen S; Hartmann JT; Hartmann M; Heidenreich A; Hoeltl W; Horwich A; Huddart R; Jewett M; Joffe J; Jones WG; Kisbenedek L; Klepp O; Kliesch S; Koehrmann KU; Kollmannsberger C; Kuczyk M; Laguna P; Galvis OL; Loy V; Mason MD; Mead GM; Mueller R; Nichols C; Nicolai N; Oliver T; Ondrus D; Oosterhof GON; Ares LP; Pizzocaro G; Pont J; Pottek T; Powles T; Rick O; Rosti G; Salvioni R; Scheiderbauer J; Schmelz H-U; Schmidberger H; Schmoll H-J; Schrader M; Sedlmayer F; Skakkebaek NE; Sohaib A; Tjulandin S; Warde P; Weinknecht S; Weissbach L; Wittekind C; Winter E; Wood L; von der Maase H
Review: EUROPEAN UROLOGY. 2008;53(3):497-513

European consensus conference on diagnosis and treatment of germ cell cancer:: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG):: Part II

Krege S; Beyer J; Souchon R; Albers P; Albrecht W; Alyaba F; Bamberg M; Bodrogi I; Bokemeyer C; Cavallin-Stahl E; Classen J; Clemm C; Cohn-Cedermark G; Culine S; Daugaard G; De Mulder PHM; De Santis M; de Wit M; de Wit R; Derigs HG; Dieckmann K-P; Dieing A; Droz J-P; Fenner M; Fizazi K; Flechon A; Fossa SD; del Muro XG; Gauler T; Geczi L; Gerl A; Germa-Lluch JR; Gillessen S; Hartmann JT; Hartmann M; Heidenreich A; Hoeltl W; Horwich A; Huddart R; Jewett M; Joffe J; Jones WG; Kisbenedek L; Klepp O; Kliesch S; Koehrmann KU; Kollmannsberger C; Kuczyk M; Laguna P; Galvis OL; Loy V; Mason MD; Mead GM; Mueller R; Nichols C; Nicolai N; Oliver T; Ondrus D; Oosterhof GON; Paz-Ares L; Pizzocaro G; Pont J; Pottek T; Powles T; Rick O; Rosti G; Saluioni R; Scheiderbauer J; Schmelz H-U; Schmidberger H; Schmoll H-J; Schrader M; Sedlmayer F; Skakkebaek NE; Sohaib A; Tjulandin S; Warde P; Weinknecht S; Weissbach L; Wittekind C; Winter E; Wood L; von der Maase H
Letter: ACTA ONCOLOGICA. 2007;46(6):862-863

Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer

Kalkner KM; Ullen A; Wersall P; Cohn-Cedermark G
Published conference paper: CANCER. 1997;80(8):1418-1425

Outcomes of patients with local recurrence of cutaneous malignant melanoma - A population-based study

CohnCedermark G; ManssonBrahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027

Examina och utbildning

Docent, onkologi, Karolinska Institutet, 2015
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2000

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI